featured
Empagliflozin, Irrespective of Systolic BP, Improves Outcomes in Patients With HFpEF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Eur Heart J 2022 Dec 07;[EPub Ahead of Print], M Böhm, S Anker, F Mahfoud, L Lauder, G Filippatos, JP Ferreira, SJ Pocock, M Brueckmann, I Saloustros, E Schüler, C Wanner, F Zannad, M Packer, J ButlerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.